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The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the
treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n¼41),
350mgm
 2 irinotecan as a 90-min i.v. infusion q3 weeks; arm B (n¼38), 125mgm
 2 irinotecan as a 90-min i.v. infusion weekly 4
weeks q6 weeks; arm C (n¼46), 250mgm
 2 irinotecan as a 90-min i.v. infusion q2 weeks; or arm D (n¼49), 10mgm
 2day
 1
irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed,
although a shorter time to treatment failure was noted for arm D (1.7 months; P¼0.02). Overall response rates were in the range
5–11%. Secondary end points included median survival (6.4–9.4 months), and time to progression (2.7–3.8 months) and treatment
failure (1.7–3.2 months). Similarly, there were no significant differences in the incidence of grade 3–4 toxicities, although the toxicity
profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic
syndrome were observed in arm D; however, there was a trend for increased gastrointestinal toxicity. Irinotecan is an effective and
safe second-line treatment for colorectal cancer. The schedules examined yielded equivalent results, indicating that there is no
advantage of the prolonged vs short infusion schedules.
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Irinotecan (CPT-11, Campto
s) is a semisynthetic water-soluble
derivative of the plant alkaloid camptothecin. Irinotecan is used
for the first- and second-line treatment of advanced colorectal
cancer following 5-fluorouracil (5-FU)-based therapy (Cunning-
ham et al, 1998; Douillard et al, 2000). Unlike other camptothecin
analogues, irinotecan is a prodrug and undergoes hydrolysis by
liver carboxylesterase to form the active metabolite SN-38 (Rivory
et al, 1996). Irinotecan specifically stabilises covalent topoisome-
rase I (TopI)–DNA cleavable complexes, which ultimately leads to
cell death (Hsiang et al, 1985, 1989a; Bjornsti et al, 1989). The
formation of the TopI-cleavable complex is reversible; it exists
only in the presence of a camptothecin-like drug (Bjornsti et al,
1989; Stewart et al, 1998). The cytotoxic effect of irinotecan and
SN-38 is cell cycle specific and therefore prolonged infusions could
increase the antitumour activity (Hsiang et al, 1989b; Burris et al,
1992).
Preclinical data and some clinical data support the use of
prolonged exposure schedules of camptothecins (Furuta and
Yokokura, 1990; Houghton et al, 1995; O’Reilly and Rowinsky,
1996). Phase I studies have employed different administration
schedules and dosages of irinotecan, including a prolonged
infusion schedule. Diarrhoea and/or neutropenia were the major
dose-limiting toxicities in these studies (Masuda et al, 1996;
O’Reilly and Rowinsky, 1996; Herben et al, 1999). Three schedules
with short infusions were used in phase II studies, a 90-min
infusion once every 3 weeks, a 90-min weekly infusion and a
fortnightly 90-min infusion (Shimada et al, 1993; Rothenberg et al,
1996; Pitot et al, 1997; Rougier et al, 1997; Cunningham et al, 1998;
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lDouillard et al, 2000). In order to further evaluate the risk–benefit
ratio of irinotecan (after failure of thymidylate synthase inhibitor-
based regimens, for example, 5-FU) at the currently recommended
dosages/schedules in patients with metastatic colorectal cancer and
to determine whether a clinically relevant schedule dependency
exists for irinotecan, this multicentre, randomised, open-label
phase II study was initiated. Patients were randomised to one of
four treatment arms: 350mgm
 2 irinotecan q3 weeks (arm A),
125mgm
 2 irinotecan weekly 4 weeks q6 weeks (arm B),
250mgm
 2 irinotecan q2 weeks (arm C) and a 14-day continuous
infusion of 10mgm
 2day
 1 q3 weeks (arm D). The primary
objective of the study was to determine and rank the response rates
of the four different irinotecan schedules. The secondary objectives
were to determine the time to progression and treatment failure,
duration of response and disease stabilisation, and survival.
Furthermore, pharmacokinetics were evaluated for arms A, B
and C, and a possible schedule dependency for irinotecan was
explored.
MATERIALS AND METHODS
Inclusion/exclusion criteria
Patients were included in the study if they had histologically
proven adenocarcinoma of the colon or rectum and metastatic
disease at study entry (within 6 months of the last thymidylate
synthase inhibitor administration). Only patients with measurable
metastatic disease were included, and if only one metastatic lesion
was present a histologic examination was mandatory. Other
inclusion criteria included: age 18–75 years, World Health
Organization (WHO) performance status (PS) p2, and estimated
life expectancy of 43 months (Anonymous, 1979). Patients had to
have sufficient haematologic function, defined as neutrophil count
X1.0 10
9l
 1, haemoglobin X6.5gdl
 1 and platelet count
X50 10
9l
 1; adequate hepatic and renal function, defined as
total bilirubin p1.5 times the upper normal limit (UNL),
transaminases p3 times UNL or p5 times when related to liver
metastases and serum creatinine p1.5 times UNL.
All patients should have received adjuvant and/or palliative
chemotherapy based on thymidylate synthase inhibitors (5-FU or
raltitrexed) within 6 months of study entry. Patients could not
have undergone chemotherapy or surgery within at least 4 weeks
before entry into the study, or 6 weeks in the case of mitomycin C,
nitrosourea or extended field radiation therapy. The overall
number of prior chemotherapy regimens could not exceed 2, if
one of them was given with adjuvant intent, or 1 if only a palliative
regimen was given. Patients had to be suitable and willing to
undergo insertion of a portable device and indwelling catheter
(Port-a-Cath).
Exclusion criteria included a history of treatment with any
topoisomerase inhibitor, chronic enteropathy (Crohn’s disease,
ulcerative colitis), bowel obstruction or sub-obstruction, prior or
current history of chronic diarrhoea, symptomatic brain metas-
tasis, current infection, other serious illness or medical conditions
or a history of other cancer, except adequately treated in situ
cervical carcinoma or nonmelanoma skin cancer. The study
protocol was approved by an independent Ethics Committee, in
agreement with local legal prescriptions. All patients gave written
informed consent.
Trial design
This was a prospective, nonblinded, multicentre, phase II study,
which planned to comprise at least 148 eligible and evaluable
patients. A total of 17 centres in Europe participated in this study:
two in Denmark, one in Ireland, four in The Netherlands, five in
Norway, two in Sweden and three in Russia. Patients were treated
with four different schedules of irinotecan. Randomisation was
performed centrally by Aventis Pharma R&D, Antony Cedex,
France. The primary end point of this study was response rate; the
Simon design was used to rank these results. A total of 37 evaluable
patients per arm had to be included. With this sample size and the
hypothesis that the lowest expected baseline response rate would
be 10%, there was a 90% probability of selecting the best treatment
group on categorical variables.
Treatment plan
Patients randomised to arm A received 350mgm
 2 irinotecan as a
90-min i.v. infusion every 3 weeks, patients in arm B received
125mgm
 2 irinotecan as a 90-min i.v. infusion weekly for 4 weeks
every 6 weeks and patients in arm C received 250mgm
 2
irinotecan as a 90-min infusion every 2 weeks. Patients in arm D
were treated with irinotecan given as a 14-day infusion at a dose
level of 10mgm
 2day
 1, which was repeated every 3 weeks. One
treatment course was defined as one 90-min infusion in arms A, B
or C (every 3 weeks, weekly or every 2 weeks, respectively) and a
continuous infusion over 14 days administered every 3 weeks in
arm D. A cycle was defined as a treatment period of 6 weeks; a
complete cycle for patients in arms A and D consisted of two
courses of irinotecan, yielding total dose intensities of 700 and
280mgm
 2 per 6 weeks, respectively, a cycle in arm B consisted of
four courses yielding a dose intensity of 500mgm
 2 per 6 weeks
and a cycle for patients in arm C consisted of three courses of
irinotecan, yielding a dose intensity of 750mgm
 2 per 6 weeks.
Toxicity and response evaluation
Pretreatment evaluation included a complete medical history and
complete physical examination. Before each course, blood
chemistry and haematology profiles were checked. Haematology
was checked weekly. Tumour measurements were performed every
other cycle (6 weeks) and responses were scored according to
WHO criteria (Anonymous, 1979). An external response review
committee (ERRC) was established during the study to perform
assessments of tumour response. All toxicities were graded
according to the National Cancer Institute-Common Toxicity
Criteria (NCI-CTC) (Anonymous, 2004). Adverse events that were
not reported according to NCI-CTC were graded as mild,
moderate, severe, or life threatening.
Pharmacokinetics
A pharmacokinetic evaluation was performed using a population
approach; 88 patients from arms A, B and C were evaluated during
the first course of treatment. The sampling strategy consisted of
three different sampling schedules (with three sampling times in
each): schedule 1: 30min before the end of the infusion, 5min and
3–4h post-infusion; schedule 2: 30min before the end of the
infusion, 10min and 5–7h post-infusion; schedule 3: 5min before
the end of the infusion, 30min and 20–24h post-infusion. In a few
cases, an additional sample was taken in schedules 1 and 2 after
24h. All patients at one site were sampled according to the same
schedule. The aim of the sampling strategy was to define the full
kinetic profile over the whole population, by drawing a small
number of samples at different times from a large number of
patients. This approach is previously referred to as the full-screen
approach (Sheiner and Benet, 1985).
Blood samples (5ml) were collected in heparinised tubes and
immediately immersed in ice-water. Plasma was obtained by
centrifugation of the samples (5min; 3000r.p.m., 41C) and stored
at  201C or lower until analysis. Plasma levels of total (lactone
plus carboxylate) irinotecan and metabolite SN-38 were deter-
mined by a reversed-phase high-performance liquid chromato-
graphy method using a fluorescence detection (Vergniol et al,
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l2000). The bio-analysis was performed in accordance with the
principles of Good Laboratory Practice (Anonymous, 2001). The
quantification limits for irinotecan and metabolite SN-38 were 10
and 2.5mgl
 1, respectively. The plasma concentration–time
profiles of irinotecan and metabolite SN-38 were analysed using
nonlinear mixed effect modelling as implemented in the NONMEM
program. Pharmacokinetic parameters were determined by the
Bayesian approach with the concentration–time data from each
patient, and a population model previously defined. A three- and
two-compartment structural model were used for irinotecan and
metabolite SN-38, respectively. The following pharmacokinetic
parameters of irinotecan and SN-38 were determined: maximum
plasma concentration (Cmax), time to reach Cmax (Tmax), area
under the plasma concentration–time curve from 0 to infinity
(AUC) and total body clearance (CL, irinotecan only) was also
estimated. The metabolic ratio of irinotecan was defined as the
ratio of the SN-38 AUC over the irinotecan AUC. Furthermore, the
AUC of SN-38 per cycle (AUCc) was estimated by multiplying the
AUC of SN-38 by the number of courses per cycle ( 2,  4 and
 3 for arms A, B and C, respectively).
Statistical analysis
The primary efficacy variable was response rate; overall response
was defined as complete plus partial response. The secondary
efficacy variables were the duration of response and stabilisation,
time to progression, time to treatment failure and the overall
survival. The differences between the four treatment groups were
explored with the w
2 test. Subsequent statistical tests were
performed only in the case of evidence of difference to provide
the significance level of difference. The Fisher exact test was used
to compare treatment groups on categorical variables. For
continuous variables, if a normal distribution could be assumed,
Student’s t-tests were used. Otherwise, they were analysed by
nonparametric methods. Exact confidence intervals were calcu-
lated using binominal distribution probability. Censored data were
analysed using the Kaplan–Meier method; the log-rank test was
used to compare the groups. Differences in pharmacokinetic
parameters between the four treatment arms were evaluated using
one-way analysis of variance (ANOVA) combined with least
significant difference (LSD) method (P was set at 0.05) and the
Student’s t-test was used to calculate the P-value of significant
differences. The Pearson correlation coefficient (r) was calculated
between dose and pharmacokinetic parameters. Statistical analyses
were performed with SPSS (version 10.0.7 for Windows, SPSS Inc.).
All tests for significance were two-tailed.
RESULTS
Patient enrollment and evaluability
A total of 174 patients entered the study. Of these patients, 168
(97%) actually received medication and comprised the intent to
treat population (treated patients analysed in the arm to which
they were assigned by randomisation). In all, 41 patients were
included in arm A, 37 patients in arm B, 46 patients in arm C and
44 patients in arm D. A total of 149 (86%) patients were not in the
per protocol population (treated, eligible and evaluable for
response). Table 1 describes the reasons why patients were in
the per protocol population. A total of 88 (51%) patients were
evaluable for pharmacokinetics. At the cutoff date, all but seven
patients had discontinued the treatment. In all treatment arms, the
majority of patients discontinued treatment because of progressive
disease: 81% in arm A, 57% in arm B, 61% in arm C and 55% in
arm D. More patients discontinued treatment due to toxicity (from
the study drug) in arm D (21%) compared with arm A (0%), arm B
(14%) and arm C (11%) (P¼0.03); the main reasons were
diarrhoea in arm B (8%) and C (7%), diarrhoea (14%) and
vomiting (14%) in arm D.
Patient characteristics
Patient characteristics at baseline were well balanced across the
four treatment arms and are summarised in Table 2. The majority
of patients had colon carcinoma. Diagnosis of the primary disease
was made more than a year before the patients were randomised.
Treatment delivery
A total of 247 courses were administered to 41 patients in arm A,
98 courses to 37 patients in arm B, 368 courses to 46 patients in
arm C and 133 courses to 44 patients in arm D. All patients
received at least one course. The median numbers of weeks on
study were 18.6, 12.0, 15.2 and 7.0 in arms A, B, C and D,
respectively. Details of treatment delivery and dose intensity are
shown in Table 3. In arm A, the main reasons for treatment delay
were vomiting and infection (two patients, two cycles); in arm B
Table 1 Reasons for noneligibility or nonevaluability for response
Reason
a Arm A Arm B Arm C Arm D
Presence or history of CNS metastasis 1 1 1
No measurable lesion 1
Patient not metastatic 1
Early discontinuation 3 1 8
Early death 1
Response not properly assessed 1
41 line palliative chemotherapy 1
Total bilirubin 41.5 UNL 1
ASAT and ALAT 45U N L 1
aA patient may have more than one reason.
Table 2 Patient and disease characteristics
Characteristics Arm A Arm B Arm C Arm D
Number of patients 41 37 46 44
Male/female 23/18 17/20 27/19 22/22
Median age (range) 60 (28–75) 58 (41–71) 62 (35–74) 60 (31–76)
Percentage of patients
WHO performance status
02 9 3 5 4 6 3 4
16 8 5 4 5 2 6 4
22 1 1 2 2
Prior therapy
Surgery 100 97 96 100
Radiotherapy 29 19 24 14
Chemotherapy 2 14 7 9
Primary tumour site
Colon 54 65 59 71
Rectum 46 35 41 30
Number of involved organs
17 1 5 4 6 5 7 3
21 2 4 1 2 6 2 1
X31 7 5 9 7
Involved organs
Liver 85 84 72 68
Lung 27 27 30 11
Lymph nodes 15 24 22 25
Soft tissue 5 0 9 18
Other 22 16 17 14
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lneutropenia (10 patients, 13 cycles); and in arms C and D
diarrhoea (five patients, five cycles and six patients, eight cycles,
respectively). Few cycles had dose reductions. The main reasons
for dose reductions were diarrhoea in arm A (four patients, four
cycles), arm C (five patients, five cycles) and arm D (seven
patients, 10 cycles) and neutropenia in arm B (seven patients,
seven cycles). More protocol-planned doses were administered in
arms A, B and C compared with arm D, where the relative dose
intensity (RDI) was the lowest.
Efficacy
Table 4 summarises the overall response rates of the full analysis
population by treatment arm. There were no significant differences
in response rate across the four treatment arms (P¼0.7). Table 5
summarises the secondary efficacy parameters. Again, no sig-
nificant differences in duration of response and disease stabilisa-
tion, time to treatment failure, time to progression or survival were
observed. However, a notably shorter time to treatment failure was
observed for arm D (1.7 months; P¼0.02).
Safety
The number of patients with at least one grade 3–4 adverse event
possibly or probably related to irinotecan administration was 12
(29%) in arm A, 11 (30%) in arm B, 14 (30%) in arm C and 22
(50%) in arm D (P¼0.1). Table 6 provides a summary of
Table 3 Irinotecan treatment and extent of exposure
Arm A Arm B Arm C Arm D
Number of patients 41 37 46 44
Total courses/cycles 247/124 392/98 368/123 133/67
Weeks on study
a 18.6 12.0 15.2 7.0
% cycles reduced 11 13 8 14
% cycles delayed 17 26 18 34
RDI
b 0.96 (0.69–1.02) 0.97 (0.60–1.11) 0.99 (0.61–1.05) 0.90 (0.21–1.04)
aMedian.
bMedian (min–max).
Table 4 Response results in the intent-to-treat population
Arm A Arm B Arm C Arm D
N % N % N % N %
Complete response 0 0 0 00012
Partial response 3 7 2 5 5 11 1 2
Stable disease 18 44 23 62 25 54 19 43
Progressive disease 19 46 7 19 15 33 15 34
Not evaluable 1 2 5 14 1 2 8 18
Overall response (CR+PR) 3 7 2 5 5 11 2 5
95% confidence interval 1.5–19.9 0.7–18.2 3.6–23.6 0.6–15.5
Table 5 Secondary efficacy parameters in the intent-to-treat population
Arm A Arm B Arm C Arm D
Months Months Months Months
Duration of response and stabilisation 5.9 (0.8–12.7) 3.9 (1.0–13.0) 5.3 (1.3–8.9) 3.4 (1.3–6.9)
Time to progression 2.7 (1.0–12.8) 3.5 (0.0–13.2) 3.8 (0.0–8.9) 2.8 (0.0–7.0)
Time to treatment failure 2.7 (1.0–12.8) 2.3 (0.6–8.3) 3.2 (0.4–7.1) 1.7 (0.5–7.1)
Survival 9.4 (1.0–15.3) 7.1 (0.6–13.5) 8.6 (0.7–16.7) 6.4 (1.1–15.1)
Data are represented as median (min–max).
Table 6 Haematologic toxicity
Arm B Arm C
Toxicity type Arm A %Patients/%Cycles Arm D
Leukocytopenia
All grades 73/70
a 68/53
a 70/56
a 30/24
b
Grade 3–4 20/15
b 14/6 15/6
b 5/3
b
Neutropenia
All grades 73
a/65
b 61
a/50 65
a/57
b 23
a/15
b
Grade 3–4 34/21 25/12 28/20 9/5
Febrile neutropenia/
neutropenic infection
75 5/2 7/1 —
2/1 — 2/1 2/1
Anaemia
All grades 98/92 92/87 91/90 91/83
Grade 3–4 2/1 3/1 4/4 0/0
Thrombocytopenia
All grades 24
c/14 11
c/6 15
c/6 9
c/8
Grade 3–4 0/0 0/0 0/0 5/3
Percentage of patients developing toxicity in all courses/percentage of cycles in which
toxicity developed; worst grade during study. Number of patients is 41 in arm A, 37
in arm B, 46 in arm C and 44 in arm D; number of cycles is 127 in arm A, 98 in arm B,
130 in arm C and 76 in arm D.
aArm D is significantly different from arms A, B and C
(Pp0.004).
bArm D is significantly different from arms A and C (Pp0.004).
cArm A is
significantly different from arms B, C and D (Pp0.001).
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lhaematologic toxicities. Haematologic toxicity consisted primarily
of leukocytopenia and neutropenia, and was generally more
pronounced in arms A, B and C compared with arm D. The
duration of neutropenia (grade 3–4) was o8 days in 53% of
episodes in arm A, 77% in arm B, 84% in arm C and 25% in arm D.
The median number of days to grade 3–4 nadir was higher in arm
D (16 days, range 14–19) compared with arm A (9 days, range 6–
17), arm B (7 days, range 4–13) and arm C (7 days, range 6–17).
The median time to recovery from grade 3–4 neutropenia was the
shortest in arm D (4 days, range 4–4) compared with arm A (7
days, range 6–14), arm B (7 days, range 2–15) and arm C (7 days,
range 1–12).
Table 7 provides a summary of observed nonhaemato-
logic toxicities. The main nonhaematologic toxicities were of
gastrointestinal origin and were observed in all treatment
arms. There was a trend towards more pronounced gastrointest-
inal toxicity in arm D. Severe diarrhoea was more frequently
reported in arms D (25.0%) and B (24.0%), but was unexpectedly
low in arm A (10%). The low rate of grade 3–4 diarrhoea in arm A
is the result of both better patient information and good
compliance to guidelines on the management of diarrhoea.
Severe nausea and vomiting were also more often noted in arm
D (23 and 16%, respectively) than in the other arms. Severe fatigue
was equally reported in arms A and D (7 and 7%, respectively).
Grade 3–4 anorexia was only reported in arm D. Other
nonhaematologic toxicities were generally mild (grade 1–2). The
incidence of alopecia was significantly less in arm D compared
with arms A and C (Po0.001), and cholinergic syndrome was
significantly less common in arm D compared to the other arms
(Po0.001).
Pharmacokinetics
Pharmacokinetic parameters of irinotecan and SN-38 are pre-
sented in Table 8. The different doses of irinotecan lead to
significant differences in the AUC and Cmax of irinotecan and SN-
38 across arms A, B and C during the first course. To compare the
three treatment arms, the AUC of SN-38 was extrapolated to AUC
per cycle (AUCc). The AUCc is significantly higher in arms A and C
compared with arm B, which is in accordance with the higher dose
administered per cycle in arms A and C. The metabolic ratio in
arms A and C was lower compared with arm B. No significant
difference in clearance of irinotecan could be observed between
arms A, B and C. We found a significant correlation between the
administered dose of irinotecan and the AUC and Cmax of
irinotecan (r¼0.69 and 0.93, respectively) and the AUC and the
Cmax of SN-38 (r¼0.59 and 0.55, respectively) (Po0.001). The
metabolic ratio of SN-38 was significantly inversely correlated with
dose (r¼ 0.39, Po0.001).
DISCUSSION
Irinotecan monotherapy is recognised as the treatment of choice
in second-line therapy (after failure of 5-FU) in metastatic
colorectal cancer (Cunningham et al, 1998; Douillard et al,
Table 7 Nonhaematologic toxicity
Arm A Arm B Arm C Arm D
All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4
Toxicity type % of patients
Gastrointestinal origin
Diarrhoea 88 10 76 24 74 13 77 25
Nausea 73 15 73 5 65 9 80 23
Vomiting 54 10 57 3 50 9 59 16
Gastrointestinal pain 17 2 16 3 17 2 23 2
Anorexia 12 — 14 — 17 — 34 5
Other
Fatigue 51 7 38 3 61 4 52 7
Fever in absence of infection 12 2 19 - 15 4 16 —
Infection 7 2 11 5 11 — 11 7
Cholinergic syndrome 68
a —4 1
a —6 1
a 27
a —
Alopecia 71
b —4 3 — 6 7
b —3 4
b —
Toxicity is expressed as % of patients with adverse events possibly or probably related to study drug medication; worst grade during study. N¼41 in arm A, 37 in arm B, 46 in
arm C and 44 in arm D.
aArm D is significantly different from arm A, B and C (Pp0.001).
bArm D is significantly different from arm A and C (Po0.001).
Table 8 Pharmacokinetic parameters of irinotecan and SN-38
Irinotecan SN-38
Arm Dose (mgm
 2) N Cl (lh
 1) Cmax (lmoll
 1) AUC (lmolhl
 1) Cmax (lmoll
 1) AUC (lmolhl
 1) AUCc (lmolhl
 1) Metabolic ratio
A 350 30 22.377.3 7.9171.10
c 47.8719.0
c 0.15170.069
d 2.0870.96
d 4.1671.93
e 0.04470.008
e
B 125 28 26.879.6 2.6270.39
c 14.676.9
c 0.06570.021
d 0.7670.29
d 3.0371.17
f 0.05470.014
e
C 250 30 24.078.4 5.5270.90
c 32.7713.5
c 0.11770.057
d 1.4870.71
d 4.4472.12
e 0.04670.010
e
140
a 6 30.478.2 ND 12.873.9 ND 1.470.3 4.270.9 0.1270.02
b
Data are listed as mean7s.d.
aData obtained in patients receiving 10mgm
 2 irinotecan as 14-day prolonged infusions (N¼6).
16 bSignificantly different from arms A–C
(Po0.001).
cSignificantly different from the other arms of treatment (Po0.001).
dSignificantly different from the other arms of treatment (Po0.05).
eSignificantly different from
arm B (Po0.05).
fSignificantly different from arms A and C (Po0.05). Abbreviations: see Materials and methods section. ND¼not determined.
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l2000). Several administration schedules have been developed in
the past; this study was set out to find the optimal schedule. This is
the first report of a randomised phase II study of irinotecan given
at four different schedules to patients with metastatic colorectal
cancer.
After analysing the primary and secondary end points, no
significant superiority of one of the four treatment schedules could
be observed; this may be because the sample size was too small.
There is a trend for an increased response rate in arm C; however,
this does not translate to better survival. In addition, the response
rate in arm D is possibly biased because of the relative high
number of nonevaluable patients, the relatively shorter duration of
treatment and the lower RDI. Median survival in this study was the
highest in arm A (9.4 months), which is comparable to the median
survival reported by Cunningham et al (1998) (9.2 months) and
Rougier et al (1997) (10.8 months) using the same schedule.
The main toxicities were of gastrointestinal origin for all four
treatment arms and haematologic toxicity was generally mild. We
found no significant differences in the intensity of toxicity;
however, there was a distinct difference in toxicity profiles. There
was a trend for increased gastrointestinal toxicity in arm D
(prolonged infusion) compared with the other treatment arms
(short infusions). Furthermore, there was significantly less
alopecia in arm D compared with arms A and C, and cholinergic
syndrome was significantly greater in arms A, B, and C compared
with arm D. The alopecia and cholinergic syndromes are probably
more closely related to peak concentrations of irinotecan and SN-
38, than to total dose intensity. This is in accordance with the
results of a phase I study with prolonged schedules of irinotecan,
where no cholinergic syndrome was observed. It has been found
that the observed cholinergic syndrome after the administration of
irinotecan is caused by a rapid reversible inhibition of acetylcho-
linesterase by irinotecan (Rivory et al, 1996). Furthermore, support
for schedule-dependent toxicity was recently given by Fuchs et al
(2003). In this study, a similar schedule as given in treatment arm
A was compared with 125mgm
 2 irinotecan weekly for 4 weeks,
followed by 2 weeks rest. A significantly lower incidence of severe
diarrhoea was reported, while efficacy was comparable for both
treatment arms. In addition, Hwang et al reported significantly less
diarrhoea when 125mgm
 2 irinotecan was administered once a
week for 2 weeks, followed by a week rest vs ‘schedule B’. However,
in this study, also significantly less nausea, vomiting and
neutropenia were observed (Hwang et al, 2003). Regarding
haematologic toxicities, leukocytopenia and neutropenia were
generally significantly milder in arm D compared with the other
treatment arms in our study. Thrombocytopenia was significantly
higher in arm A compared with the other treatment arms. These
differences in toxicity profile are probably related to the schedule
of administration rather than the dose per cycle (highest in arm C)
or the exposure to SN-38 per cycle (lowest in arm B). Schedule
dependency of topo-isomerase I inhibitors, with regard to
cytotoxicity, was also shown in vitro and in vivo in tumour-
bearing mice and in clinical studies with different camptothecins
(Burris et al, 1992; Dodds and Rivory, 1999; Gerrits et al, 1999).
The results of an early phase II study with irinotecan support the
use of prolonged exposure schedules in patients with lymphomas
(Ohno et al, 1990). Schedule dependency of irinotecan in patients
with solid tumours is less obvious (Takeuchi et al, 1991; Sakata
et al, 1994). Tumour response and safety of irinotecan may not
only be schedule dependent but also tumour-type dependent.
Increased carboxylesterase activity has been found in some tumour
types and might influence conversion of irinotecan to SN-38
(Wakui and Taguchi, 1992; Guichard et al, 1999). Systemic
exposure to SN-38 was found to be higher in mice bearing human
neuroblastoma xenografts as compared with nontumour-bearing
mice (Guichard et al, 1999).
We compared our pharmacokinetic parameters with the
pharmacokinetics of patients treated with a prolonged infusion
of irinotecan as described by Herben et al (1999), which is similar
to the schedule used in arm D. We found a significant difference in
exposure to SN-38 as estimated by the AUCc. The exposure to SN-
38 was increased in arms A and C compared with arm B. The
estimated exposure per cycle to SN-38 of patients treated by 14-day
prolonged infusion of 10mgm
 2day
 1 irinotecan was comparable
with arms A and C (Table 8) (Herben et al, 1999). This difference
in exposure did not lead to differences in activity between arm B
and arms A and C, nor could it explain for the differences found in
toxicity profile. The AUC and Cmax were strongly correlated with
the dose of irinotecan. The metabolic ratios of SN-38 after the short
infusions in arms A, B and C found in this study were 0.04, 0.05
and 0.04, respectively. A similar metabolic ratio was also found in a
previous study where a metabolic ratio of 0.05 was noted after a
standard 90-min infusion of 350mgm
 2 irinotecan (Rougier et al,
1997). This is lower than the metabolic ratio of 0.12, as found for
the prolonged infusion of irinotecan (Table 8) (Herben et al, 1999).
The difference in metabolic ratio between bolus and prolonged
infusions agrees with other previously published data (Chabot et al,
1995; Gupta et al, 1997; Zamboni et al, 1998). We also found a
significant difference between the metabolic ratio of SN-38
between arms A and B, and B and C. A low, but very significant
inverse correlation between dose and metabolic ratio of SN-38 was
observed for arms A, B and C. A possible explanation for this
change in metabolic ratio is saturation of the carboxylesterase
reaction. The carboxylesterase reaction converting irinotecan into
SN-38 in humans is very inefficient and deacylation dependent
(Rivory et al, 1996; Haaz et al, 1997; Takimoto et al, 2000). The
saturability of this enzymatic reaction may be of relevance for
prolonged infusion schedules of irinotecan. The metabolic ratio of
SN-38 is not solely dependent on the formation of SN-38 by
carboxylesterases, but also on the effect of dose on the metabolism
of irinotecan via other pathways, such as the formation of APC, the
saturation of its conversion to SN-38 glucuronide or enterohepatic
recycling. SN-38, the active metabolite of irinotecan, is about a
100–1000 times more potent topo-isomerase I inhibitor than its
parent compound in vitro models (Slatter et al, 1997). The
observed extensive metabolism of irinotecan to its active form, SN-
38, may thus explain in part the low recommended dose for the
continuous infusion schedule (Herben et al, 1999). The extent of
metabolism of irinotecan to SN-38 seems to be dependent upon the
administration schedule and administered dose of irinotecan. This
effect has no clinical relevance with the administration schedules
used in arms A, B and C (short infusions). However, it provides a
rationale for prolonged administration schedules with low-dose
irinotecan, despite the slightly less favourable toxicity profile of
prolonged intravenously administrated irinotecan, as found in this
study.
Recently, an oral formulation of irinotecan has been developed
and has entered phase I clinical trials (Schoemaker et al, 2002).
Since chronic infusions are cumbersome and expensive, an oral
formulation provides an excellent method to administer irinotecan
over a prolonged period at low doses. However, future studies
should examine whether the balance between efficacy and safety is
most optimal in chronic (oral) treatment schedules.
In summary, the four irinotecan schedules used in this study can
generally be considered equivalent, in terms of efficacy and
toxicity. However, more patients may have been required for us to
observe any significant differences. The schedule used in arm D
resulted in more gastrointestinal toxicity but the least haemato-
logic toxicity. Prolonged intravenous administration of irinotecan
(arm D) showed no clinical benefit over the short infusion
schedules and is therefore not a feasible treatment option because
of the disadvantages associated with this mode of administration.
Irinotecan can be administered safely as a second-line treatment to
patients with colorectal cancer according to local clinical practice,
using either weekly, every 2-week or every 3-week short infusion
schedules.
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